

98-16-02

CP 1653

CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)				Docket No.
Applicant(s): IHLENFELDT et al.				BMID9918CUS
Serial No. 10/025,826	Filing Date December 19, 2001	Examiner To Be Assigned	Group Art Unit 1653	
Invention: STABILIZED AQUEOUS NUCLEOSIDE TRIPHOSPHATE SOLUTIONS				
				
<p>I hereby certify that this <u>Invention Disclosure Statement</u> <small>(Identify type of correspondence)</small></p>				
<p>is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: The Assistant Commissioner for Patents, Washington, D.C. 20231 on <u>August 15, 2002</u> <small>(Date)</small></p>				
<p><u>Michele Wilson</u> <small>(Typed or Printed Name of Person Mailing Correspondence)</small></p>				
<p> <small>(Signature of Person Mailing Correspondence)</small></p>				
<p><u>EL841986580US</u> <small>("Express Mail" Mailing Label Number)</small></p>				
<p>Note: Each paper must have its own certificate of mailing.</p>				
<p>RECEIVED AUG 20 2002 TECH CENTER 1600/2900</p>				

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
**BMID9918CUS**

In Re Application Of: **IHLLENFELDT et al.**


Serial No.  
**10/025,826**

Filing Date  
**December 19, 2001**

Examiner  
**To Be Assigned**

Group Art Unit  
**1653**

Title: **STABILIZED AQUEOUS NUCLEOSIDE TRIPHOSPHATE SOLUTIONS**



Address to:

**Assistant Commissioner for Patents  
Washington, D.C. 20231**

**37 CFR 1.97(b)**

1.  The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

**37 CFR 1.97(c)**

2.  The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

the statement specified in 37 CFR 1.97(e);

**OR**

the fee set forth in 37 CFR 1.17(p).

**RECEIVED**

AUG 20 2002

201 CENTER 1600/2900

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
BMID9918CUS

In Re Application: **IHLLENFELDT et al.**

Serial No.  
**10/025,826**

Filing Date  
**December 19, 2001**

Examiner  
**To Be Assigned**

Group Art Unit  
**1653**

**STABILIZED AQUEOUS NUCLEOSIDE TRIPHOSPHATE SOLUTIONS**



**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- A check in the amount of \_\_\_\_\_ is attached.  
 The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. **50-0877** as described below. A duplicate copy of this sheet is enclosed.  
 Charge the amount of \_\_\_\_\_  
 Credit any overpayment.  
 Charge any additional fee required.

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F)

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

**Certificate of Mailing by First Class Mail**

I certify that this document and fee is being deposited with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Signature of Person Mailing Correspondence

Typed or Printed Name of Person Mailing Certificate

\*This certificate may only be used if paying by deposit account.

  
Signature

Dated: **8/14/02**


Kenneth J. Waite, Reg. No. 45,189  
Roche Diagnostics Corporation  
9115 Hague Road, Bldg. D  
P.O. Box 50457  
Indianapolis, IN 46250-0457  
Telephone: (317) 521-3104  
Facsimile: (317) 521-2883

CC:


**RECEIVED**

AUG 20 2002

TECH CENTER 1600/2900

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				ATTY DOCKET NO. <b>BMID9918CUS</b>		SERIAL NO. <b>10/025,826</b>	
				<b>IHLLENFELDT et al.</b>			
				FILING <b>December 19, 2001</b>	GROUP <b>1653</b>		
<b>U.S. PATENT DOCUMENTS</b>							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	1	<b>5,432,065</b>	<b>07/95</b>	Fuller	<b>435</b>	<b>91.1</b>	
	2	<b>5,811,072</b>	<b>09/98</b>	Price et al.	<b>424</b>	<b>1.73</b>	
							
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES      NO
3		<b>EP 0632134 A2</b>	<b>01/95</b>	Europe	<b>C12Q</b>	<b>1/68</b>	
4		<b>EP 0649909 A2</b>	<b>04/95</b>	Europe	<b>C12Q</b>	<b>1/68</b>	<input checked="" type="checkbox"/> ABSTRACT
5		<b>EP 0751226 A2</b>	<b>01/97</b>	Europe	<b>C12Q</b>	<b>1/68</b>	
6		<b>4078 M</b>	<b>04/66</b>	France	<b>A61K</b>		<input checked="" type="checkbox"/> ABSTRACT
7		<b>2674253</b>	<b>09/92</b>	France	<b>C12Q</b>	<b>1/68</b>	<input checked="" type="checkbox"/> ABSTRACT
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
RECEIVED				AUG 2 0 2002			
EXAMINER				DATE CONSIDERED			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)			ATTY DOCKET NO. BMID9918CUS		SERIAL NO. 10/025,826		
			IHLENFELDT et al.		FILING December 19, 2001		GROUP 1653
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
							
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
	8	WO 92/03556	03/92	PCT	C12N	15/54	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
	9	WO 96/14405	05/96	PCT	C12N	15/00	<input type="checkbox"/> YES <input checked="" type="checkbox"/> NO
	10	WO98/21362	05/98	PCT	C12Q	1/68	<input checked="" type="checkbox"/> ABSTRACT
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	11	Ausubel, F. M., "Current Protocols in Molecular Biology," 1987, John Wiley & Sons, Inc. XP002062215, pp. 3.4.1-3.4.3.					
	12	GIBCO BRL Catalogue & Reference Guide, 1992, pages 298-300					
EXAMINER			DATE CONSIDERED		TECH CENTER 1600/2900		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE CITATION</b> <i>(Use several sheets if necessary)</i>		Docket Number (Optional) <b>BMID9918CUS</b>	Application Number <b>10/025,826</b>
		Applicant(s) <b>IHLENFELDT, et al.</b>	
		Filing Date <b>December 21, 2001</b>	Group Art Unit <b>1653</b>
*EXAMINER INITIAL	OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>		
13	Perkin Elmer Cetus (catalog, 1988) "GeneAmp DNA Amplification Reagent Kit"		
14	Promega catalog (1992-1993, page 170 and web site)		
15	Promega website ( <a href="http://egi.promega.com/catalog/catinfo.asp?idx=1018">http://egi.promega.com/catalog/catinfo.asp?idx=1018</a> )		
16	Sambrook et al., "Molecular Cloning: A Laboratory Manual." 1992, 10.6-10.17 and 13.3-13.6		
			
<b>RECEIVED</b> <b>AUG 20 2002</b>			
EXAMINER		DATE CONSIDERED	
		TECH CENTER 1600/2900	

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.